• Citer

VIP and pituitary adenylate cyclase activating polypeptide (PACAP) have an antiproliferative effect on the T98G human glioblastoma cell line through interaction with VIP2 receptor.

par Vertongen, Pascale ;Camby, Isabelle ;Darro, Francis;Kiss, Robert ;Robberecht, Patrick
Référence Neuropeptides, 30, 5, page (491-496)
Publication Publié, 1996-10

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	VIP and pituitary adenylate cyclase activating polypeptide (PACAP) have an antiproliferative effect on the T98G human glioblastoma cell line through interaction with VIP2 receptor.
Auteur:	Vertongen, Pascale; Camby, Isabelle; Darro, Francis; Kiss, Robert; Robberecht, Patrick
Informations sur la publication:	Neuropeptides, 30, 5, page (491-496)
Statut de publication:	Publié, 1996-10
Sujet CREF:	Sciences bio-médicales et agricoles
MeSH keywords:	Adenylate Cyclase -- metabolism
	Brain Neoplasms -- pathology
	Cell Cycle -- drug effects
	Cell Division -- drug effects
	DNA Replication -- drug effects
	DNA, Neoplasm -- biosynthesis
	Enzyme Activation -- drug effects
	Glioblastoma -- pathology
	Growth Inhibitors -- pharmacology
	Humans
	Neoplasm Proteins -- drug effects
	Neoplasm Proteins -- physiology
	Neuropeptides -- pharmacology
	Pituitary Adenylate Cyclase-Activating Polypeptide
	Polymerase Chain Reaction
	RNA, Messenger -- biosynthesis
	Receptors, Vasoactive Intestinal Peptide -- drug effects
	Receptors, Vasoactive Intestinal Peptide -- physiology
	Receptors, Vasoactive Intestinal Peptide, Type II
	Tumor Cells, Cultured -- drug effects
	Vasoactive Intestinal Peptide -- pharmacology
Note générale:	Comparative Study
	Journal Article
	Research Support, Non-U.S. Gov't
Langue:	Anglais
Identificateurs:	urn:issn:0143-4179
	info:pii/S0143-4179(96)90015-3
	info:pmid/8923513
	VX-001639